Revvity (RVTY) has recently drawn investor attention after a period of weaker share performance, with the stock showing negative returns over the past week, month, past 3 months and year.
See our latest analysis for Revvity.
With the share price at $95.59 and a 30 day share price return of 12.14% decline, recent weakness builds on a softer trend, as the 1 year total shareholder return of 13.16% decline and 3 year total shareholder return of 25.03% decline point to fading momentum despite revenue and net income growth over the last reported year.
If Revvity’s recent moves have you reassessing your watchlist, this could be a good moment to broaden your search. You could use our 28 healthcare AI stocks as a starting point for other ideas in the space.
With Revvity trading at $95.59 alongside an indicated intrinsic discount of around 31% and a value score of 4, the key question is whether this reflects an undervalued healthcare name or if the market is already pricing in future growth.
Most Popular Narrative: 16.6% Undervalued
Revvity’s most followed valuation narrative pegs fair value at $114.63, comfortably above the current $95.59 share price, which places that recent weakness in a different light.
Ongoing shift in product mix toward higher margin, software enabled and consumables driven offerings (e.g., SaaS Signals, reagents, new IDS i20 platform), along with structural cost actions, are expected to materially expand operating and net margins, with 2026 set to start at a higher 28% operating margin baseline.
There is a full earnings playbook behind that margin ramp, linking mid single digit revenue growth to much faster profit expansion and a lower future earnings multiple than today, which may be of interest to investors who want to understand how those pieces fit together across cash flows, discount rate and expected buybacks without seeing all the numbers upfront.
Result: Fair Value of $114.63 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, that upside story can quickly change if China reimbursement and trade pressures deepen, or if weaker academic and government funding continues to keep organic growth under strain.
Find out about the key risks to this Revvity narrative.
Next Steps
If this combination of concerns and potential has you undecided, take a closer look at the numbers and form your own view quickly, starting with 3 key rewards and 1 important warning sign.
Ready to hunt for more investment ideas?
If this story has sharpened your thinking, do not stop here, the next opportunity on your list could come from a company you have not considered yet.
- Lock in potential value by scanning our 45 high quality undervalued stocks and see which names currently line up with solid fundamentals and a discounted price tag.
- Balance risk and reward by checking out a 76 resilient stocks with low risk scores that focuses on companies with steadier profiles and fewer red flags.
- Get ahead of the crowd with a screener containing 24 high quality undiscovered gems that highlights quality businesses investors may not be watching closely yet.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com